EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | A211640 | AUROBINDO PHARMA LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Gilead Sciences, Inc. et al v. Aurobindo Pharma Ltd. et al 2 patentsANDA 211640emtricitabine and tenofovir disoproxil fumarate | D. Del. | 2018-05-18 | Terminated 2018-10-10 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$10.19
per ea
Lowest NADAC/Unit
$10.19
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 59651016530EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 100-150 MG TAB | $10.19 | EA | Generic | — | 2026-04-22 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.